P7
Bulevirtide monotherapy prevents liver decompensation but not HCC in patients with HDV-related cirrhosis: 3-year results from an inverse proba-bility-weighted European case-controlled study
E. Degasperi, A. De Silvestri, D. Roulot, MP. Anolli, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, J. Foucher, S. Metivier, M. Buti, A. Palom, G. D’Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Pap
P8
Long-term clinical and virological outcomes of Bulevirtide monotherapy up to 4 years in CHD patients with cirrhosis: the SAVE-D study
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D’Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeye
P9
Characterization of virological breakthroughs under Bulevirtide monotherapy: combined data from the SAVE-D and D-SHIELD cohorts
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, A. Loglio, A. Ciancio, G. D’Offizi, C. Schramm, T. Reiberge, MR. Brunetto, K. Agarwal, M. Buti, S. Zaltron, F. Tacke, H. Wedemeyer, M. Papatheodoridi, F. Van Bömmell, S. Lens,
P10
Bulevirtide provides comparable virological control regardless of cirrhosis status: analysis of treatment response and breakthroughs from the D-Shield multicenter prospective study
MP. Anolli, E. Degasperi, G. D’Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, MR. Brunetto, B. Coco, A. Zaltron, O. Nozza, M. Milella, E. Ros-selli Del Turco, L. Turco, A. Di Lorenzo, M. Tamé, P. Toniutto, A. Gasbarrini, L. Marinaro, FP
P12
Improvement of non-invasive fibrosis tests and clinically significant portal hypertension according to Baveno VII criteria during Bulevirtide mo-notherapy in patients with HDV-related cirrhosis: a longitudinal analysis of the SAVE-D study
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D’Offizi, F. De Maria, C. Zöllner, F. Tacke, Q. Wu, H. Wedemeyer, M. Papa
P13
Bulevirtide discontinuation after long-term HDV RNA suppression in patients with CHD: impact of different HDV RNA assays on patient selection and virological outcomes (Robogene 2.0 vs. AltoStar 1.5)
MP. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
P14
Integrated Pharmacogenetic, Pharmacokinetic, and Clinical Evaluation of Bulevirtide in Patients with Chronic Hepatitis D
J. Cusato, M. Antonucci, A. Palermiti, A. Manca, A. De Nicolò, C. Quarta, A. D’Avolio, G. Di Perri, S. Bonora and L. Marinaro
P15
Mathematical modeling of HDV RNA, ALT and HBsAg kinetics during initial and repeat bulevirtide monotherapy
D. Shemla, K. Deterding, L. Shekhtman, S.J. Cotler, A. Mhlanga, E. Degasperi, P. Lampertico, D. Sambarino, L. Sandmann, K. Port, S. Aleman, A. Olsen, M. Jachs, T. Reiberger, M. Brunetto, G. Ricco, H. Dahari, H. Wedemeyer
P16
Real-world effectiveness and safety of Bulevirtide in patients with chronic hepatitis D: a single-center cohort from Romania
V. Molagic, I. Staicu, A. Mihalache, A. Saran, A. Cozma, D. Neagu, A. Marinescu, C. Gheorghe, C. Tiliscan, R. Nastase, D. Toma, A. Negru, A. Orfanu, S. Arama, V. Arama
P17
Correlation between HDV RNA and anti-HDV dynamics in chronic hepatitis D patients treated with Bulevirtide
G. Ricco, D. Cavallone, P. Colombatto, B. Coco, F. Oliveri, F. Damone, G. Petralli, V. Romagnoli, A. Salvati, L. Surace, A. Calì, B. Vianello, F. Bonino, M. R. Brunetto
P20
Real-world 72-week virological and biochemical responses to bulevirtide in Romanian patients with chronic hepatitis D: data from a multicentre registry
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diculescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob
P21
Health-related quality of life during bulevirtide treatment in a Romanian cohort
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diculescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob
P23
Mathematical modeling of 144-week bulevirtide monotherapy in HDV-infected patients with compensated cirrhosis and CSPH
A. Mhlanga, L. Shekhtman, E. Degasperi, M.P. Anolli, S.C. Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, A. Callegaro, S.J. Cotler, H. Dahari, P. Lampertico
